Phase II for BioGard
Thursday, 15 January, 2009
Melbourne company Immuron, formerly known as Anadis, announced its BioGard hyperimmune bovine colostrum product will be studied in a Phase II trial in early stage HIV patients.
BioGard contains anti-lipopolysaccharide antibodies to reduce microbial translocation and immune activation in the gut and other mucosal surfaces. The study will be conducted at Case Western Reserve University hospital in the US.
Last year, the company announced the product would be part of the multi-national Phase IV CORAL study, in conjunction with Merck’s new integrase inhibitor Isentress (raltegravir). That study is set to begin this month.
In addition, a new formulation containing antibodies against HIV envelope antigens will be undertaken by the University of Melbourne’s Associate Professor Damian Purcell, following a research grant awarded by the Department of Health and Ageing.
Overuse of inhalers can increase heart attack risk
Overuse of reliever inhalers is associated with higher risks of developing and dying from...
Unhealthy Western diet could accelerate cognitive decline
An unhealthy Western-style diet is associated with a faster cognitive decline in people with a...
Cancer drug enters clinical trials based on a false mechanism
A cancer drug currently being tested in patients appears to have entered clinical trials based on...
